| __timestamp | Novavax, Inc. | Rhythm Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 19928000 | 1213000 |
| Thursday, January 1, 2015 | 30842000 | 3425000 |
| Friday, January 1, 2016 | 46527000 | 6311000 |
| Sunday, January 1, 2017 | 34451000 | 9518000 |
| Monday, January 1, 2018 | 34409000 | 28080000 |
| Tuesday, January 1, 2019 | 34417000 | 36550000 |
| Wednesday, January 1, 2020 | 145290000 | 46125000 |
| Friday, January 1, 2021 | 298358000 | 68486000 |
| Saturday, January 1, 2022 | 488691000 | 92032000 |
| Sunday, January 1, 2023 | 468946000 | 117532000 |
Unveiling the hidden dimensions of data
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for financial health. Over the past decade, Rhythm Pharmaceuticals, Inc. and Novavax, Inc. have taken different paths in this regard. From 2014 to 2023, Novavax's SG&A expenses surged by over 2,250%, peaking in 2022. In contrast, Rhythm Pharmaceuticals maintained a more conservative growth, with expenses increasing by approximately 9,600% over the same period, yet starting from a much lower base.
While Novavax's expenses skyrocketed, reflecting its aggressive expansion and operational scaling, Rhythm Pharmaceuticals' steadier increase suggests a more controlled approach. This divergence highlights the strategic choices companies make in balancing growth with cost management. As investors and stakeholders evaluate these companies, understanding their SG&A trends offers valuable insights into their operational strategies and financial discipline.
Eli Lilly and Company and Novavax, Inc.: SG&A Spending Patterns Compared
Selling, General, and Administrative Costs: Takeda Pharmaceutical Company Limited vs Rhythm Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: Summit Therapeutics Inc. vs Rhythm Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing BioMarin Pharmaceutical Inc. and Rhythm Pharmaceuticals, Inc.
Comparing SG&A Expenses: BioMarin Pharmaceutical Inc. vs Novavax, Inc. Trends and Insights
Catalent, Inc. or Novavax, Inc.: Who Manages SG&A Costs Better?
SG&A Efficiency Analysis: Comparing Ascendis Pharma A/S and Rhythm Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Ultragenyx Pharmaceutical Inc. and Rhythm Pharmaceuticals, Inc.
Comparing SG&A Expenses: CymaBay Therapeutics, Inc. vs Novavax, Inc. Trends and Insights
SG&A Efficiency Analysis: Comparing CRISPR Therapeutics AG and Rhythm Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Rhythm Pharmaceuticals, Inc. and PTC Therapeutics, Inc.
Rhythm Pharmaceuticals, Inc. and Vericel Corporation: SG&A Spending Patterns Compared